DelveInsight's "LUXTURNA Market Size, Forecast, and Market Insight Report" highlights the details around LUXTURNA, a one-time ...

The entire 36-week data for the remaining subjects in the trial is anticipated in the second quarter of this year.

The investigators retrospectively evaluated 126 consecutive treatment-naïve nAMD patients (126 eyes) who received a loading ...

Continuous administration of ranibizumab with a port delivery system provides an alternative to frequent intravitreal injections for diabetic macular edema and helps delay progression of ...

Patients with diabetic macular edema previously treated with a ranibizumab biosimilar in India experience comparable safety ...

Macular degeneration, particularly age-related macular degeneration, is a leading cause of vision loss worldwide. This ...

In the context of retinal surgery, Bernstein would be able ... while using the surgical robot device to perform subretinal injections while also avoiding eye complications. "Robotics has taken ...

In Germany, there are an estimated 1.6 million anti-VEGF retina injections each year, with over half of those injections representing use of off-label, repackaged bevacizumab. For Germany ...

Additionally, the prognosis of macular edema may help clinicians evaluate renal function, investigators reported ...

LUXTURNA has significant market potential due to the high unmet need for effective treatments in rare genetic conditions. With its FDA approval for specific mutations in the RPE65 gene, it offers ...